Model N Tackles Life Sciences Regulations changes Head On

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Model N Tackles Life Sciences Regulations changes Head On With Regulatory Update Program

REDWOOD CITY, Calif., July 1, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Model N, Inc. (NYSE: MODN), the leading revenue management provider to the life sciences and technology industries, today announced the expansion of the Model N Regulatory Update Program -- a program that every Model N Government Compliance customer is automatically enrolled in at no extra charge.

On June 18, CMS announced changes of new fields and features in the Drug Data Reporting for the Medicaid (DDR) system, which will be effective starting July 19 and will impact most manufacturer's June and Q2 2014 filings due by July 30th. Next on the horizon, the AMP Final Rule will significantly affect manufacturers contracting with the government. The Model N Regulatory Update Program addresses both of these issues.

Over 60 percent of pharmaceutical executives perceive regulatory and legislative issues to be the "most significant barrier to their company's growth," according to a study conducted by KPMG that surveyed 107 senior pharmaceutical executives, with 45 percent of respondents working at companies with annual revenues over $10 billion.

Regulatory change introduces complexity and organizational plus reputational risk, where one wrong price calculation can cost you millions of dollars in leaked revenue and enormous fines.

The Model N Regulatory Update Program was created to engage customers to rapidly identify, develop, test and deliver solutions required by major regulatory changes. Model N gathers input on additional tools and solutions manufacturers need to respond to changes, and provides customers with timely and robust resources, events and information.

Key Components and Benefits:

  • Swiftly receive Regulatory Update Packs to ensure systems, calculations, and reporting are up-to-date
  • Engage in webinars and events with industry experts to delve into best practices, the impact of the Affordable Care Act (ACA), and how to prepare for upcoming changes
  • Receive regulatory update emails to ensure notification of late-breaking regulation changes
  • Compare and learn from other manufacturers by participating in industry benchmark surveys
  • Influence product direction by providing feedback regarding what additional tools and solutions are needed to effectively and efficiently respond to regulatory changes
  • Access rich resources and videos to better understand vital aspects of regulation changes and their impact.
"Model N is committed to keeping our customers current on required calculations and reporting in the Model N Government Compliance solution and informed of the latest developments in regulations and requirements," said Dr. Scott Medberry, director of product management at Model N. Since enactment of the ACA in 2010, Model N has delivered the following solution updates through Regulatory Update Packs:
  • Authorized business user configuration of Medicaid minimum rates
  • Unit Rebate Amount (URA) changes for:
o New formulations
o Clotting factor/Pediatric drugs
o Cap at 100 percent of AMP
o Line extensions
  • PHS price calculation update
  • 5i Drug Filtering in price type calculations
  • AMP Unit reporting
  • NFAMP/FCP changes for newly launched products
  • Medicaid Record ID and ROSI/PQAS updates
  • ASP Addendum A and DDR product file changes

Connect with Model N
LinkedIn
Twitter (@ModelN)
Facebook
Model N Blog
Google+
YouTube

About Model N

Model N is the leader in Revenue Management solutions. Model N helps its customers maximize their revenue and reduce revenue compliance risk by managing every dollar that impacts their top line encompassing contracting, pricing, incentives, and rebates. Model N leverages its deep industry expertise to support the unique business needs of Life Sciences and Technology companies in more than 50 countries. Global Customers include: Actavis, Allergan, Amgen, Atmel, Boston Scientific, Bristol-Myers Squibb, Dell, Johnson & Johnson, Linear Technology, Merck, Marvell, Maxim, Micron, Nokia, Novartis, Novo Nordisk, ON Semiconductor, and STMicroelectronics. Learn more at: http://www.modeln.com . Model N is traded on the New York Stock Exchange under the symbol MODN.

Legal

Model N® is a registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Contact

Brenda Christensen
Model N
Tel: 818.307.9942
Email: bchristensen(at)modeln(dot)com

Amanda Jones
Connect Marketing
Tel: 801.373.7888
Email: amandaj(at)connectmarketing(dot)com

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2014/06/prweb11978948.htm

Model N, Inc. Brenda Christensen +1 (650) 610-4717

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 271

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 338

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 126

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 382

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 445

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 246

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 314

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 250

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 155

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Century Communities Celebrates New Home Community Launch

Updated Category News Views 171

Exciting Grand Opening for Willow Glenn Community Century Communities, Inc. (NYSE: CCS), a prominent national homebuilder, is thrilled to announce the upcoming Grand Opening for Willow Glenn, a remarkable new residential community featuring spacious, modern two-story homes. Situated with breathtaking views of Mt. Rainier, this community is designed to elevate the living...

Continue Reading
Universal Health Services Welcomes Darren Lehrich as New VP

Updated Category News Views 161

Universal Health Services Announces New Addition to Leadership Universal Health Services, Inc. (NYSE: UHS), a key player in the healthcare sector, has recently welcomed Darren Lehrich to its leadership team as Vice President of Investor Relations. In his new capacity, Lehrich will report directly to CFO Steve Filton, aiming to enhance investor engagement in this critical...

Continue Reading
Provident Financial Services Achieves Impressive Q3 Earnings Results

Updated Category News Views 62

Recent Earnings Update Provident Financial Services, Inc. (NYSE: PFS) has recently shared its financial results for its third quarter, showcasing a remarkable net earnings figure of $46.4 million, equivalent to $0.36 per share. These encouraging results were shared by CEO Tony Labozzetta during a call with investors. He highlighted the successful integration of the...

Continue Reading
EnviroGold Global Strengthens Board with New Executive Appointment

Updated Category News Views 71

EnviroGold Global Welcomes Jackie Przybylowski to Board EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) is thrilled to announce that Jackie Przybylowski, a distinguished executive in the mining and capital markets sector, has joined its Board of Directors. This pivotal appointment takes effect as the company progresses the rollout of its innovative NVRO...

Continue Reading
Syensqo Reports Strong Q4 and Full Year 2024 Performance

Updated Category News Views 754

Syensqo's Remarkable Fourth Quarter and Full Year 2024 Performance Syensqo recently announced its highlights for the fourth quarter and full year of 2024, showcasing impressive growth in a challenging market landscape. This performance reflects the company's resilience and strategic vision. Quarter Four Achievements During Q4 of 2024, Syensqo achieved net sales of €1.6...

Continue Reading